| Peer-Reviewed

Double-positive Anti-glomerular Basement Membrane Disease in a Child with Crescentic Glomerulonephritis: A Case Report and Review of Literature

Received: 28 December 2020     Accepted: 14 January 2021     Published: 23 February 2021
Views:       Downloads:
Abstract

‘Double-positive’ with anti-glomerular basement membrane (anti-GBM) antibody and anti-neutrophil cytoplasmic antibody (ANCA) is an extremely rare cause of small vessel vasculitis in children. Studies have reported a distinct hybrid phenotype in double-positive patients which requires an aggressive treatment approach. The data on double positive children are scarce with few case reports available with varied outcomes. A case of 9-year-old girl from India who had double-positive anti-GBM disease is reported here. The patient presented with complaints of edema, oliguria, gross hematuria with rising creatine and was diagnosed as rapidly progressive glomerulonephritis (RPGN). Histological examinations of linear immunoglobulin G deposits along with glomerular capillaries were suggestive of anti-GBM disease. The anti-GBM and p-ANCA antibody titers were also high, and the aforementioned findings led to a diagnosis of ‘double-positive’ anti-GBM with RPGN. She was treated with standard plasma exchange therapy along with pulse methyl prednisolone (3 doses of 30 mg/kg/day on Days 1 to 3), oral prednisolone (1.5 mg/kg on Day 4), single intravenous injection of cyclophosphamide (500 mg/m2 on Day 5) and mycophenolate mofetil (MMF; 1000 mg/m2 on Day 6) followed by maintenance treatment with oral prednisolone (1 mg/kg/day) and MMF (800 mg/m2/day) from Day 7 onwards. Overall, the anti-GBM and p-ANCA levels declined throughout the treatment period but the patient progressed towards end stage renal disease.

Published in American Journal of Pediatrics (Volume 7, Issue 1)
DOI 10.11648/j.ajp.20210701.14
Page(s) 14-18
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Anti-GBM, p-ANCA, Double-Positive, Small Vessel Vasculitis, Children

References
[1] Goodpasture EW (2009) Landmark publication from The American Journal of the Medical Sciences: The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 338: 148-51.
[2] Canney M and Little MA (2017) ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype. Kidney International 92: 544-6.
[3] McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M and Pusey CD (2017) Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney international 92: 693-702.
[4] J DEZ, Taylor D, Thein H and Yehia M (2011) Incidence and features of dual anti-GBM-positive and ANCA-positive patients. Nephrology (Carlton) 16: 725-9.
[5] Jain R, Dgheim H and Bomback AS (2018) Rituximab for Anti-Glomerular Basement Membrane Disease. Kidney international reports 4: 614-8.
[6] Nasr SH, Collins AB, Alexander MP, Schraith DF, Herrera Hernandez L, Fidler ME, Sethi S, Leung N, Fervenza FC and Cornell LD (2016) The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int 89: 897-908.
[7] Levy JB, Hammad T, Coulthart A, Dougan T and Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66: 1535-40.
[8] Segelmark M, Hellmark T and Wieslander J (2003) The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94:c59-68.
[9] Bogdanović R, Minić P, Marković-Lipkovski J, Stajić N, Savić N and Rodić M (2013) Pulmonary renal syndrome in a child with coexistence of anti-neutrophil cytoplasmic antibodies and anti-glomerular basement membrane disease: case report and literature review. BMC nephrology 14: 66.
[10] Paueksakon P, Hunley TE, Lee SM and Fogo AB (1999) A 12-year-old girl with pulmonary hemorrhage, skin lesions, and hematuria. Am J Kidney Dis 33: 404-9.
[11] Hijosa MM, Román LE, Camblor CF, García ML, Salcedo DP and Torres MN (2005) Anti-GBM and anti-MPO antibodies coexist in a case of pulmonary renal syndrome. Pediatr Nephrol 20: 807-10.
[12] Naidoo S and Waller S (2009) Anti-GBM antibodies co-exist with MPO-ANCA in a 4-year-old girl with acute renal failure. Pediatr Nephrol 24: 215-6.
[13] Williamson SR, Phillips CL, Andreoli SP and Nailescu C (2011) A 25-year experience with pediatric anti-glomerular basement membrane disease. Pediatr Nephrol 26: 85-91.
[14] Xie L-j, Cui Z, Jia X-y, Chen Z, Liu X-r and Zhao M-h (2015) Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report. Medicine 94:e1179-e.
[15] Timmermans SAMEG, van Dam MJCM, Vink E, Horuz FAPT, van Paassen P and Rosias PPR (2019) Rituximab for the Treatment of Pediatric Double-Positive Small-Vessel Vasculitis. Kidney international reports 5: 235-8.
Cite This Article
  • APA Style

    Subal Kumar Pradhan, Snehamayee Nayak. (2021). Double-positive Anti-glomerular Basement Membrane Disease in a Child with Crescentic Glomerulonephritis: A Case Report and Review of Literature. American Journal of Pediatrics, 7(1), 14-18. https://doi.org/10.11648/j.ajp.20210701.14

    Copy | Download

    ACS Style

    Subal Kumar Pradhan; Snehamayee Nayak. Double-positive Anti-glomerular Basement Membrane Disease in a Child with Crescentic Glomerulonephritis: A Case Report and Review of Literature. Am. J. Pediatr. 2021, 7(1), 14-18. doi: 10.11648/j.ajp.20210701.14

    Copy | Download

    AMA Style

    Subal Kumar Pradhan, Snehamayee Nayak. Double-positive Anti-glomerular Basement Membrane Disease in a Child with Crescentic Glomerulonephritis: A Case Report and Review of Literature. Am J Pediatr. 2021;7(1):14-18. doi: 10.11648/j.ajp.20210701.14

    Copy | Download

  • @article{10.11648/j.ajp.20210701.14,
      author = {Subal Kumar Pradhan and Snehamayee Nayak},
      title = {Double-positive Anti-glomerular Basement Membrane Disease in a Child with Crescentic Glomerulonephritis: A Case Report and Review of Literature},
      journal = {American Journal of Pediatrics},
      volume = {7},
      number = {1},
      pages = {14-18},
      doi = {10.11648/j.ajp.20210701.14},
      url = {https://doi.org/10.11648/j.ajp.20210701.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20210701.14},
      abstract = {‘Double-positive’ with anti-glomerular basement membrane (anti-GBM) antibody and anti-neutrophil cytoplasmic antibody (ANCA) is an extremely rare cause of small vessel vasculitis in children. Studies have reported a distinct hybrid phenotype in double-positive patients which requires an aggressive treatment approach. The data on double positive children are scarce with few case reports available with varied outcomes. A case of 9-year-old girl from India who had double-positive anti-GBM disease is reported here. The patient presented with complaints of edema, oliguria, gross hematuria with rising creatine and was diagnosed as rapidly progressive glomerulonephritis (RPGN). Histological examinations of linear immunoglobulin G deposits along with glomerular capillaries were suggestive of anti-GBM disease. The anti-GBM and p-ANCA antibody titers were also high, and the aforementioned findings led to a diagnosis of ‘double-positive’ anti-GBM with RPGN. She was treated with standard plasma exchange therapy along with pulse methyl prednisolone (3 doses of 30 mg/kg/day on Days 1 to 3), oral prednisolone (1.5 mg/kg on Day 4), single intravenous injection of cyclophosphamide (500 mg/m2 on Day 5) and mycophenolate mofetil (MMF; 1000 mg/m2 on Day 6) followed by maintenance treatment with oral prednisolone (1 mg/kg/day) and MMF (800 mg/m2/day) from Day 7 onwards. Overall, the anti-GBM and p-ANCA levels declined throughout the treatment period but the patient progressed towards end stage renal disease.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Double-positive Anti-glomerular Basement Membrane Disease in a Child with Crescentic Glomerulonephritis: A Case Report and Review of Literature
    AU  - Subal Kumar Pradhan
    AU  - Snehamayee Nayak
    Y1  - 2021/02/23
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ajp.20210701.14
    DO  - 10.11648/j.ajp.20210701.14
    T2  - American Journal of Pediatrics
    JF  - American Journal of Pediatrics
    JO  - American Journal of Pediatrics
    SP  - 14
    EP  - 18
    PB  - Science Publishing Group
    SN  - 2472-0909
    UR  - https://doi.org/10.11648/j.ajp.20210701.14
    AB  - ‘Double-positive’ with anti-glomerular basement membrane (anti-GBM) antibody and anti-neutrophil cytoplasmic antibody (ANCA) is an extremely rare cause of small vessel vasculitis in children. Studies have reported a distinct hybrid phenotype in double-positive patients which requires an aggressive treatment approach. The data on double positive children are scarce with few case reports available with varied outcomes. A case of 9-year-old girl from India who had double-positive anti-GBM disease is reported here. The patient presented with complaints of edema, oliguria, gross hematuria with rising creatine and was diagnosed as rapidly progressive glomerulonephritis (RPGN). Histological examinations of linear immunoglobulin G deposits along with glomerular capillaries were suggestive of anti-GBM disease. The anti-GBM and p-ANCA antibody titers were also high, and the aforementioned findings led to a diagnosis of ‘double-positive’ anti-GBM with RPGN. She was treated with standard plasma exchange therapy along with pulse methyl prednisolone (3 doses of 30 mg/kg/day on Days 1 to 3), oral prednisolone (1.5 mg/kg on Day 4), single intravenous injection of cyclophosphamide (500 mg/m2 on Day 5) and mycophenolate mofetil (MMF; 1000 mg/m2 on Day 6) followed by maintenance treatment with oral prednisolone (1 mg/kg/day) and MMF (800 mg/m2/day) from Day 7 onwards. Overall, the anti-GBM and p-ANCA levels declined throughout the treatment period but the patient progressed towards end stage renal disease.
    VL  - 7
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Paediatrics, Sardar Vallav Bhai Patel Post Graduate Institute of Pediatrics and Srirama Chandra Bhanja Medical College, Cuttack, Odisha, India

  • Department of Paediatrics, Sardar Vallav Bhai Patel Post Graduate Institute of Pediatrics and Srirama Chandra Bhanja Medical College, Cuttack, Odisha, India

  • Sections